Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å vurdere effektiviteten, sikkerheten og farmakokinetikken til EYU688 hos pasienter med denguefeber

9. november 2026 oppdatert av: Novartis Pharmaceuticals

En randomisert, deltaker- og etterforsker-blind, placebokontrollert, parallell gruppestudie for å vurdere effektiviteten, sikkerheten og farmakokinetikken til EYU688 hos pasienter med denguefeber

The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.

Studieoversikt

Status

Rekruttering

Forhold

Detaljert beskrivelse

This is a randomized, participant- and investigator- blinded, placebo-controlled study to investigate the efficacy and safety of EYU688 administered orally in patients with dengue fever.

Due to the different PK sampling schedules applied, the study consists of two cohorts run in parallel (intensive PK [cohort 1] and sparse PK sampling [cohort 2]).

Studietype

Intervensjonell

Registrering (Antatt)

108

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Novartis Pharmaceuticals

Studiesteder

    • Amazonas
      • Manaus, Amazonas, Brasil, 69040-000
        • Rekruttering
        • Novartis Investigative Site
    • Federal District
      • Brasília, Federal District, Brasil, 71635-580
        • Rekruttering
        • Novartis Investigative Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 90560-032
        • Rekruttering
        • Novartis Investigative Site
    • Rio de Janeiro
      • Rio de Janeiro, Rio de Janeiro, Brasil, 21040-360
        • Rekruttering
        • Novartis Investigative Site
    • São Paulo
      • Sorocaba, São Paulo, Brasil, 18040-425
        • Rekruttering
        • Novartis Investigative Site
      • São Caetano do Sul, São Paulo, Brasil, 09521-160
        • Rekruttering
        • Novartis Investigative Site
      • São José do Rio Preto, São Paulo, Brasil, 15090 000
        • Rekruttering
        • Novartis Investigative Site
    • Atlántico
      • Barranquilla, Atlántico, Colombia, 080012
        • Rekruttering
        • Novartis Investigative Site
    • Santander Department
      • Bucaramanga, Santander Department, Colombia, 681017
        • Rekruttering
        • Novartis Investigative Site
    • Valle del Cauca Department
      • Cali, Valle del Cauca Department, Colombia, 760032
        • Rekruttering
        • Novartis Investigative Site
    • Karnataka
      • Belagavi, Karnataka, India, 590010
        • Rekruttering
        • Novartis Investigative Site
    • Maharashtra
      • Mumbai, Maharashtra, India, 400008
        • Tilbaketrukket
        • Novartis Investigative Site
      • Pune, Maharashtra, India, 411013
        • Rekruttering
        • Novartis Investigative Site
    • Rajasthan
      • Jaipur, Rajasthan, India, 302017
        • Rekruttering
        • Novartis Investigative Site
    • Tamil Nadu
      • Chennai, Tamil Nadu, India, 600113
        • Rekruttering
        • Novartis Investigative Site
      • Kuala Selangor, Malaysia, 68000
        • Rekruttering
        • Novartis Investigative Site
    • Pahang
      • Kuantan, Pahang, Malaysia, 25200
        • Rekruttering
        • Novartis Investigative Site
    • Perak
      • Ipoh, Perak, Malaysia, 30450
        • Rekruttering
        • Novartis Investigative Site
    • Pulau Pinang
      • Seberang Jaya, Pulau Pinang, Malaysia, 13700
        • Rekruttering
        • Novartis Investigative Site
    • Sarawak
      • Miri, Sarawak, Malaysia, 98000
        • Rekruttering
        • Novartis Investigative Site
      • Oaxaca City, Mexico, 68020
        • Rekruttering
        • Novartis Investigative Site
      • Veracruz, Mexico, 91855
        • Rekruttering
        • Novartis Investigative Site
      • Singapore, Singapore, 169608
        • Rekruttering
        • Novartis Investigative Site
    • Singapore
      • Singapore, Singapore, Singapore, 308433
        • Rekruttering
        • Novartis Investigative Site
      • Haiphong, Vietnam, 180000
        • Rekruttering
        • Novartis Investigative Site
      • Hanoi, Vietnam, 100000
        • Rekruttering
        • Novartis Investigative Site
      • Ho Chi Minh City, Vietnam, 700000
        • Rekruttering
        • Novartis Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 60 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female, 18 - 60 years old (inclusive).
  • History or presence of fever (≥ 38°C). At least one of the following criteria indicating dengue infection:
  • Nausea or vomiting.
  • Presence of rash, aches or pains including headache, muscle or joint pain.
  • Onset of fever ≤ 48 hours prior to treatment start.
  • Positive test on dengue fever.

Exclusion Criteria:

  • Participants with any of abnormalities of clinical laboratory parameters.

  • Usage of any anticoagulant drugs.

  • Current significant medical conditions or illness that the investigator considers should exclude the participants, especially those that require continuation of other medications likely to have an interaction with the study drug.

  • Pregnant or nursing (lactating) women.

  • Clinical signs and symptoms for severe dengue according to Dengue Guideline (WHO 2009) at screening.

  • Participants with any of the following abnormalities of clinical laboratory parameters at screening:

    • Hemoglobin <12.0 g/dL in males; <11.0 g/dL in females
    • Hematocrit >52 % in males; >46 % in females
    • Absolute neutrophil count <1500/μL
    • Platelet count <80,000/mm3
    • Creatinine >165 μmol/L in males; >130 μmol/L in females
    • Serum creatine kinase > 600 U/L
    • ALT, AST levels more than 3 X upper limit of normal (ULN)
    • Total bilirubin >24 μmol/L
  • Usage of PPIs (proton pump inhibitor) which could affect absorption of EYU688 due to stomach pH value increase up to 48 hours prior to screening.

  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 4 days after stopping of investigational drug.

  • History or long-QT syndrome, or clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening:

    • QTcF > 450 msec (males)
    • QTcF > 460 msec (females)

Other protocol-defined inclusion/exclusion criteria may apply.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Matching placebo

Matching placebo administered orally as capsules

Eksperimentell: EYU688

EYU688 administered by oral route

EYU688 administered by oral route

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Viremia reduction (viral load reduction (VLR) on log scale) at 48 hours post treatment start
Tidsramme: From predose to 48 hours post treatment start

Efficacy assessment of EYU688. It will allow to quantify the viremia reduction at 48 hours post treatment start from baseline.

From predose to 48 hours post treatment start

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Time from fever onset to start of the first 48 hours period during which the oral temperature remained below 37.5℃
Tidsramme: From fever onset to Day 15

Efficacy assessment of EYU688. It will allow to assess the time needed between fever onset and defervescence.

From fever onset to Day 15
Time from fever onset to the first of two consecutive negative viremia by PCR
Tidsramme: From fever onset to Day 15

Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day15

From fever onset to Day 15
Area under the log-transformed viremia curve (AUC) from the first dose to Day 15
Tidsramme: From fever onset to Day 15

Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day 15

From fever onset to Day 15
Changes of viral load over time
Tidsramme: From baseline to Day 15

Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day15

From baseline to Day 15
Incidence and severity of Adverse Events (AEs)
Tidsramme: From inclusion to Day 15

Incidence and severity of AEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.

From inclusion to Day 15
Incidence and severity of Serious Adverse Events (SAEs)
Tidsramme: From inclusion to Day 35

Incidence and severity of SAEs by treatment group

From inclusion to Day 35
Change of white blood cell count over time from baseline
Tidsramme: From baseline to Day 15

Assessment of safety and tolerability of EYU688

From baseline to Day 15
Change of platelet count over time
Tidsramme: From baseline to Day 15

Assessment of safety and tolerability of EYU688

From baseline to Day 15
Change of hematocrit level and percentage increase from baseline over time
Tidsramme: From baseline to Day 15

Assessment of safety and tolerability of EYU688

From baseline to Day 15
Change of AST, ALT levels over time
Tidsramme: From baseline to Day 15

Assessment of safety and tolerability of EYU688

From baseline to Day 15
No warning signs by day 7 of fever onset
Tidsramme: From inclusion to Day 15

Assessment of the dengue fever clinical evolution under EYU688

From inclusion to Day 15
Diagnosis of severe dengue fever
Tidsramme: From inclusion to Day 15

Assessment of the dengue fever clinical evolution under EYU688

From inclusion to Day 15
Diagnosis of dengue hemorrhagic fever (DHF)
Tidsramme: From inclusion to Day 15

Assessment of the dengue fever clinical evolution under EYU688

From inclusion to Day 15
Plasma leakage
Tidsramme: From inclusion to Day 15

Assessment of the dengue fever clinical evolution under EYU688

From inclusion to Day 15
Requiring fluid infusion
Tidsramme: From inclusion to Day 15

Assessment of the dengue fever clinical evolution under EYU688

From inclusion to Day 15
Time from fever onset to clinical recovery
Tidsramme: From fever onset to Day 15

Assessment of the dengue fever clinical evolution under EYU688

From fever onset to Day 15
PK parameter (Cmax)
Tidsramme: From Day 1 to Day 6

Pharmacokinetic assessment of EYU688 in dengue fever patients

From Day 1 to Day 6
PK parameter (Tmax)
Tidsramme: From Day 1 to Day 6

Pharmacokinetic assessment of EYU688 in dengue fever patients

From Day 1 to Day 6
PK parameter (partial AUCs)
Tidsramme: From Day 1 to Day 6

Pharmacokinetic assessment of EYU688 in dengue fever patients

From Day 1 to Day 6
PK concentrations following multiple doses
Tidsramme: From Day 1 to Day 6

Pharmacokinetic assessment of EYU688 in dengue fever patients

From Day 1 to Day 6

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

20. februar 2024

Primær fullføring (Antatt)

22. juli 2027

Studiet fullført (Antatt)

30. juli 2027

Datoer for studieregistrering

Først innsendt

17. august 2023

Først innsendt som oppfylte QC-kriteriene

17. august 2023

Først lagt ut (Faktiske)

23. august 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere